%20(1200%20x%20675%20px)%20(650%20x%20400%20px).png)
The rapid rise in demand for GLP-1 weight-loss medicines has created new risks for patients and new pressures for regulators, according to the British College of Aesthetic Medicine (BCAM).
As counterfeit ‘skinny jabs’ enter the UK market and online prescribing models come under scrutiny, the organisation is urging patients to treat GLP-1 as prescription-only medicines – not quick fixes.
For aesthetic practitioners, the situation will feel familiar. We have seen similar patterns before with botulinum toxin and dermal fillers: high demand, rising prices, informal supply chains and, ultimately, patient harm. The difference now is that these medicines act systemically, affecting metabolic health, appetite regulation and multiple organ systems.
At Hamilton Fraser, we believe innovation must always sit alongside protection. And the current GLP-1 landscape is a clear reminder of why governance, sourcing and clinical oversight matter.
Recent research suggests that around 1.6 million adults in the UK have used GLP-1 weight-loss medications such as Wegovy and Mounjaro in the past year alone.
As demand has surged, so too have concerns about safety. In late 2025, the Medicines and Healthcare products Regulatory Agency (MHRA), which updated its guidance for GLP1s in January 2026, dismantled the UK’s first known illicit production facility for weight-loss medicines. Investigators uncovered thousands of counterfeit injection pens, raw chemical ingredients and sophisticated packaging equipment at a warehouse on the outskirts of Northampton.
Unlicensed pens pre-filled with GLP-1 compounds, including tirzepatide, were seized, with the haul valued at more than £250,000. The site was believed to be supplying illegal weight-loss injections at scale to the UK market.
Unlike licensed medicines, counterfeit or illegally compounded GLP-1 products offer no guarantee of dose, purity or sterility. The potential consequences range from ineffective treatment and unexpected side effects to serious illness and, in extreme cases, life-threatening harm.
The pattern mirrors long-standing risks seen in cosmetic injectables, where counterfeit fillers and botulinum toxin have repeatedly entered circulation through informal supply chains.
BCAM has drawn a clear comparison. In response, it has expanded its public safety campaign, Vet It Before You Get It, to explicitly include GLP-1 weight-loss medicines alongside cosmetic injectables.
Sadie Van Sanden Cooke, chief operating officer of BCAM, says, “Whether it’s a dermal filler or a GLP-1 injection, the risk is the same if sourcing, prescribing and governance aren’t robust.
Licensed GLP-1 medicines should only be prescribed following an appropriate medical screening and consultation, and supplied through a regulated pharmacy, with clear patient information, proper cold-chain handling and access to follow-up care.”
For practitioners, the message is clear: supply chain integrity and prescribing governance are not optional extras. They are central to patient safety and professional protection.
Concerns have intensified following an investigation by ITV, which revealed that some online pharmacies approved weight-loss drugs using manipulated images. Reporters were able to obtain prescriptions, including tirzepatide, by submitting edited photographs designed to exaggerate body size, despite having healthy body mass index scores.
Under guidance from the General Pharmaceutical Council (GPhC), prescribers must independently verify weight, height and body mass index, and make sure there is two-way clinical communication before issuing prescriptions.
Following inspections, two pharmacies involved were found not to meet regulatory standards, with another remaining under investigation.
Health Secretary Wes Streeting has since confirmed that the Government is “looking very closely” at the prescribing environment for weight-loss medications, amid concerns that inconsistent standards are exposing patients to avoidable harm.
The direction of travel is clear: scrutiny will increase. And practitioners involved in weight management services must ensure their processes can withstand that scrutiny.
The regulatory spotlight comes as GLP-1 innovation accelerates globally. In December 2025, the US Food and Drug Administration approved the first oral GLP-1 medication for chronic weight management, a daily Wegovy tablet developed by Novo Nordisk. The drug became available in the US in January 2026, with UK regulatory decisions still pending.
While oral formulations may broaden access, easier administration does not reduce clinical responsibility.
Dr Nester Demosthenous, aesthetic practitioner and trustee of BCAM, comments, “GLP-1 therapies, injectable or oral, are powerful medical tools. They must be prescribed responsibly, with proper medical oversight and alongside nutritional and muscle-protective strategies. These are not cosmetic shortcuts. Safety, suitability and long-term metabolic health must always come first.”
For clinics operating at the intersection of aesthetics, wellness and longevity, this is a pivotal moment. The integration of weight management into aesthetic practice can deliver meaningful patient benefit. But it must be underpinned by:
Anything less exposes both patients and practitioners to unnecessary risk.
As aesthetic medicine continues to converge with metabolic health and longevity, the lessons from injectables are directly relevant to GLP-1 therapies: innovation without regulation invites harm.
Dr Sophie Shotter, president of BCAM, puts it plainly: “For many people, GLP-1 medication can be a genuinely transformative tool, but it should always be started with proper medical support. Rising prices must never push patients into cutting corners with their health. A trusted prescriber and a reputable, regulated pharmacy are essential. If something appears significantly cheaper, that alone should prompt careful questioning.”
At Hamilton Fraser, we have long supported practitioners in navigating emerging treatments responsibly. As the UK’s leading provider of medical malpractice insurance to the aesthetics sector, we understand how quickly innovation can outpace governance.
Our role is to help you make better decisions today, to protect your practice tomorrow.
If you offer, or are considering offering, GLP-1 weight management services, ask yourself:
Rising demand brings opportunity. But it also brings responsibility.
By applying the same governance standards to GLP-1 therapies as we do to botulinum toxin, dermal fillers and regenerative injectables, we can help ensure that innovation strengthens the sector rather than undermines it.
If you would like to review your current cover or discuss how weight management treatments fit within your medical malpractice insurance policy, speak to the Hamilton Fraser team or get an online quote today.
You can also access our Content Hub for more content, including podcasts and guides. Check out our:
%20(1200%20x%20675%20px)%20(650%20x%20400%20px)%20(300%20x%20300%20px)%20(650%20x%20500%20px).png)
.png)
